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Varicella zoster virus (VZV) typically causes chickenpox upon primary infection. In rare
cases, VZV can give rise to life-threatening disease in otherwise healthy people, but the
immunological basis for this remains unexplained. We report 4 cases of acute severe VZV
infection affecting the central nervous system or the lungs in unrelated, otherwise healthy
children who are heterozygous for rare missense mutations in POLR3A (one patient),
POLR3C (one patient), or both (two patients). POLR3A and POLR3C encode subunits of
RNA polymerase III. Leukocytes from all 4 patients tested exhibited poor IFN induction in
response to synthetic or VZV-derived DNA. Moreover, leukocytes from 3 of the patients
displayed defective IFN production upon VZV infection and reduced control of VZV
replication. These phenotypes were rescued by transduction with relevant WT alleles. This
work demonstrates that monogenic or digenic POLR3A and POLR3C deficiencies confer
increased susceptibility to severe VZV disease in otherwise healthy children, providing
evidence for an essential role of a DNA sensor in human immunity.
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Introduction
Varicella zoster virus (VZV) is a human pathogenic alphaherpes-
virus, and the causative agent of varicella (chickenpox) during 
primary infection and zoster (shingles) during reactivation from 
latency in sensory ganglia (1, 2). In rare cases, VZV primary 
infection or reactivation can cause more severe diseases, includ-
ing pneumonitis and CNS disease, manifesting as cerebellitis, 
encephalitis, or stroke (1). The frequencies of VZV CNS infec-
tion and pneumonia during primary infection in children are 
about 0.02% and 0.25%, respectively (3), and certain countries 
have introduced a VZV vaccine with the Oka strain, resulting in 
reduced frequency of VZV infection cases (4). Antiviral therapy 
with acyclovir is used for treatment of VZV encephalitis, pneu-
monitis, and certain cases of varicella in pregnant women and 
patients with a known immunodeficiency. However, despite 
treatment with acyclovir, the incidence and severity of sequelae 
following severe VZV infection are considerable (3).
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(PAMPs) to mount protective immune responses, 
including production of cytokines and IFNs (24). 
Different classes of PRRs are involved in recognition 
of virus infections, including membrane-associated 
TLRs; cytosolic retinoic acid–inducible gene 1–like 
(RIG-I–like) receptors, which sense RNA; and DNA 
sensors (24). Each of these classes of PRRs stimulates 
production of IFNs, which exhibit antiviral activity 
through their ability to induce IFN-stimulated genes 
(ISGs). With respect to DNA sensors, TLR9 detects 
unmethylated DNA, RNA polymerase III (POL III) 
recognizes AT-rich DNA, while gamma-interferon- 
inducible protein 16 (IFI16) and cyclic GMP-AMP 
synthase (cGAS) sense double-stranded DNA in a sequence- 
independent manner (25–29). Based on the current knowledge 
on the IFN induction pathways, we searched for gene mutations 
that may underlie susceptibility to severe VZV infection in whole 
exome sequencing (WES) data of 21 unrelated children with severe 
acute VZV infection. Here we describe 4 children with severe clin-
ical manifestations of VZV infection who carried heterozygous 
missense mutations in POLR3A and/or POLR3C encoding two 
subunits of the intracellular DNA sensor POL III.
Results
Identification of heterozygous mutations in POLR3A and POLR3C 
in 4 children with acute severe VZV infection. Genomic DNA from 
21 children with severe acute VZV infection was subjected to 
WES. Due to the low incidence of severe acute VZV infection, we 
decided to first focus on novel or very rare mutations (minor allele 
frequency [MAF] <0.0001 in the ExAC database (http://exac. 
broadinstitute.org/), which contains WES data of 60,706 individu-
als; as well as the in-house WES database of the Human Genetics 
of Infectious Diseases [HGID] laboratory, which contains WES 
data of 3,055 individuals with diverse infectious diseases). We 
searched for rare nonsynonymous (including missense, stop loss 
or stop gain, start loss, in-frame or frameshift insertions or dele-
tions) and splice site mutations, in a comprehensive list of genes 
known to be involved in IFN immunity (Supplemental Table 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI92280DS1). This search led to the identifica-
tion of 3 heterozygous missense mutations in POLR3A (M307V, 
Q707R, R437Q) in 3 children (P2, P3, P4), respectively; and 2 
heterozygous missense mutations in POLR3C (L11F, R438G) in 2 
children (P1, P3), respectively. Interestingly, P3 is heterozygous for 
both POLR3A and POLR3C missense mutations. We therefore fur-
ther looked for POLR3A or POLR3C variations with a MAF <0.01 
in the ExAC database and <0.005 in the 1000 Genomes database 
(http://www.internationalgenome.org/), and found that P4 is 
also heterozygous for an R84Q variation in POLR3C. Therefore, 
a total of 4 of 21 patients carry heterozygous missense mutations 
in POLR3A and/or POLR3C encoding two subunits of the intra-
cellular DNA sensor POL III (Table 1). Using the same criteria, no 
other immunity genes, including genes encoding other subunits 
of POL III, were found to be mutated in more than two patients 
in the cohort; there was a significant enrichment of mutations in 
the exomes of the severe VZV infection cohort compared with (i) 
exomes of patients in the HGID database with infectious diseases 
The VZV isolates exhibit little sequence variability, which does 
not correlate with virulence (5), suggesting that defective host 
immunity is a major determinant of disease severity, rather than 
differences between virus strains. Several different primary immu-
nodeficiencies (PIDs) within both the innate and adaptive immune 
system have previously been recognized to predispose to infection 
with VZV as well as a range of other pathogens. These include dis-
seminated VZV infection in children with SCID or NK cell defect 
(6–8). More recently, additional conditions conferring increased 
susceptibility to VZV infection have been described, including loss-
of-function mutations in GATA2, DOCK2, DOCK8, IFNGR1 and 
TYK2 (9–13). Inherited GATA2 haploinsufficiency causes NK cell 
deficiency, and an NK cell–deficient patient reported with severe 
VZV infection was subsequently found to have GATA2 deficiency 
(8, 14). Patients with any of the above underlying conditions are 
vulnerable to a wide range of severe infections. Otherwise, the cel-
lular basis of severe VZV infection in patients with those conditions 
remains largely unknown. Moreover, severe VZV disease is often 
striking in otherwise healthy children and adolescents, in whom a 
specific impairment of anti-VZV immunity might be involved.
In recent years, it has emerged that single-gene inborn errors 
of innate or cell-intrinsic immunity can underlie enhanced sus-
ceptibility to specific (viral) infections in otherwise healthy indi-
viduals (15, 16). A striking example is that mutations in genes 
controlling Toll-like receptor (TLR) 3-dependent type I and III 
IFN–mediated immunity confer susceptibility to herpes simplex 
encephalitis (HSE) (17–22). Notably, these genetic defects often 
appear to display incomplete penetrance, in which case they can 
be designated as monogenic but not Mendelian (18, 20, 23). Com-
mon to the identified genetic defects in the TLR3 pathway is that 
they lead to reduced type I and III IFN induction in patients cells 
after HSV-1 infection or stimulation through the TLR3 pathway ex 
vivo. In contrast, no PIDs leading to selectively enhanced suscep-
tibility to severe VZV infection have yet been identified. In some 
patients with PIDs conferring various infectious phenotypes, 
including severe VZV infection, impaired type I IFN production 
(autosomal recessive [AR] DOCK2 deficiency) or responses (AR 
TYK2 deficiency) have been observed among other immuno-
logical phenotypes. We hypothesize that severe VZV disease in 
some otherwise healthy individuals may be caused by monogenic 
inborn errors of IFN immunity not necessarily displaying com-
plete clinical penetrance.
The innate immune system utilizes pattern recognition recep-
tors (PRRs) to detect pathogen-associated molecular patterns 
Table 1. Genetic data and predictions in POL III mutations in VZV patients
Patient (diagnosis) Gene Variation MAF (from ExAC) CADD
P1 (VZV encephalitis) POLR3CA L11F 0 23.4
P2 (VZV cerebellitis) POLR3A M307V 0 15.5
P3 (VZV pneumonitis) POLR3A Q707R 0 19.1
P3 POLR3C R438G 0.00001647 22.7
P4 (VZV encephalitis) POLR3A R437Q 0 35.0
P4 POLR3C R84Q 0.005311 23.1
AGene IDs: POLR3A, 11128; POLR3C, 10623.
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were of European ancestry, and no consanguinity was reported. P1 
and P2, two Belgian boys, were aged 3 and 5 years, respectively 
when they were seen in hospital due to VZV encephalitis (P1) and 
cerebellitis (P2). P3 and P4, one boy and one girl, born to French 
and German parents, respectively, were aged 5 and 11 years when 
they developed VZV pneumonitis (P3) and encephalitis (P4). A 
summary of the clinical infection history of the patients and avail-
able whole blood immunophenotyping is given in Supplemental 
Tables 3 and 4. In the patients exomes, no mutations were found 
in the genes encoding proteins in the TLR3 pathway; other DNA 
sensing pathways, including cGAS, IFI16, and STING; or other 
proteins in the signaling pathways leading to IFN production. No 
other than severe VZV infection or (ii) exomes in the ExAC data-
base. Importantly, mutations in POLR3A or POLR3C were signifi-
cantly enriched in the severe VZV infection cohort (VZV cohort 
vs. control cohort consisting of 1,220 individuals of the HGID 
cohorts with non-viral infections and 2,504 individuals from the 
1000 Genomes database, either under a monogenic inheritance 
model [ethnic origin–adjusted P = 0.002 and 0.0046 for POLR3A 
and POLR3C, respectively] or under a digenic inheritance model 
[ethnic origin–adjusted P = 0.0012]; Supplemental Table 2).
Monogenic and digenic POLR3A, POLR3C mutations may under-
lie severe VZV infection with incomplete clinical penetrance. The 4 
patients, who did not have a history of unusually severe infections, 
Figure 1. Heterozygous mutations in POLR3A and POLR3C in patients with acute severe 
VZV infection. (A) Pedigrees for the families with allele segregation. Family members 
heterozygous for the same mutations as that of the probands are indicated by a vertical line. 
Gray shading: individuals affected by a relevant clinical phenotype, although not precisely 
the same as what affected the probands. (B) Illustration of the localization of the identified 
mutations in POLR3A and POLR3C. eWH, extended winged helix; CC, coiled coil. (C) PBMC 
lysates from P1–P4 and two healthy controls were analyzed for protein levels of POLR3A, 
POLR3C, and β-actin by immunoblotting. (D) Schematic representation of POL III highlight-
ing the subunits in the different subcomplexes. (E) Cryo-EM structure of POL III with the 
identified mutations highlighted in red. (F) Close-up image of the POLR3A-POLR3C interface 
harboring 4 of the 6 identified mutations.
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the predicted Mutation Significance Cutoffs (MSC) of 95% confi-
dence (Supplemental Figure 3) (32, 33). The genes themselves are 
highly conserved and subject to purifying selection, with low gene 
damage index and purification coefficient (34). Immunoblotting 
of peripheral blood mononuclear cell (PBMC) lysates from P1–P4 
for levels of POLR3A and POLR3C revealed that these proteins 
were expressed at levels comparable to those in healthy controls 
(Figure 1C). Collectively, these findings suggest that heterozygous 
mutations in the POLR3A and POLR3C genes may underlie life- 
threatening VZV disease, and the inheritance mode may be mono-
genic (P1, P2) or digenic (P3, P4).
Structural modeling of POLR3A and POLR3C mutations. POL 
III is a multi-subunit protein complex consisting of 17 subunits, 
which are organized into different subcomplexes, involved in 
DNA/RNA binding, initiation of transcription, enzymatic activ-
ity, and termination of transcription (Figure 1D) (30). When we 
modeled the mutations from each of the 4 patients onto the cryo- 
electron microscopy structure of Saccharomyces cerevisiae POL III, 
we found that two of the three POLR3A mutations were localized 
in regions exposed to the surface (P3, Q707R; P4, R437Q) (Figure 
1E), while the third POLR3A mutation (P2, M307V) and all of the 
3 POLR3C mutations localized to buried parts of the proteins at 
or close to the POLR3A-POLR3C interface (P2, M307V) (Figure 
1F and Supplemental Table 5). To test the impact of the muta-
mutations were found in other known PID genes. Sanger sequenc-
ing confirmed the POLR3A and POLR3C mutations (Supplemen-
tal Figure 1), and familial segregation suggested incomplete pen-
etrance in the case of monogenic POLR3A or POLR3C mutations 
(P1, P2) (Figure 1A). One of the two siblings of P2, a non-identical 
twin brother, carried the same POLR3A M307V mutation as P2 
and experienced chickenpox twice. No other mutation carriers 
from the two families have experienced severe infection due to 
VZV or other viruses. Higher but still incomplete clinical pene-
trance may apply in the case of digenic POLR3A and POLR3C 
mutations (P3 and P4 families), as the father of P3, who carried 
the same heterozygous mutations in POLR3A and POLR3C as P3, 
had cytomegalovirus encephalitis at the age of 20 years. No clin-
ical varicella has been reported for the father of P3. No biological 
material was available from the father of P4, while her mother 
carried the same heterozygous POLR3A R437Q mutation as P4. 
The father of P4’s mother, from whom no biological material 
was available, experienced suspected viral meningitis at the age 
of 16 years. Figure 1B depicts the localization of the mutations in 
the POLR3A and POLR3C proteins, which are part of the active 
site and initiation subcomplex of POL III, respectively (30, 31). 
All mutations lie within highly conserved regions of the proteins 
(Supplemental Figure 2). All the identified mutations have Com-
bined Annotation-Dependent Depletion (CADD) scores above 
Figure 2. Impaired DNA-stimulated 
induction of IFNs in PBMCs from 
patients with mutations in POL 
III genes. (A and B) PBMCs from 3 
healthy controls were sorted into the 
indicated cell types and transfected 
with poly(dA:dT) (2 μg/ml), herring 
testes (HT) DNA (2 μg/ml), or poly(I:C) 
(2 μg/ml). Total RNA was harvested 
6 hours later, and levels of IFNA2 
mRNA were determined by RT-qPCR. 
Mono, monocytes. (C) RNA from 
untreated PBMCs from P1–P4 and 
controls was analyzed for levels of 5S 
rRNA. (D–H) Levels of IFNA2, IFNB, 
and IFNL1 mRNA were determined 
by RT-qPCR, in total PBMC RNA 
harvested 6 hours after stimulation, 
in PBMCs from P1–P4 and a panel of 
4 healthy controls were transfected 
with (E and F) poly(dA:dT) (2 μg/
ml) or (H) poly(I:C) (4 μg/ml); (G) 
PBMCs from 3 VZV patients not 
carrying POLR3 mutations and 4 
healthy controls were transfected 
with poly(dA:dT) (2 μg/ml). For all 
PCR data, the levels of the mRNA of 
interest were normalized to GAPDH, 
and data are presented as mean ± SD 
of 3 replicates from 3 independent 
experiments. Ctrl, controls. Average 
of 4 sex- and age-matched controls. 
NS, P > 0.05; *0.01 < P < 0.05; **0.01 
< P < 0.001; ***0.001 < P < 0.0001. 
Groups were compared pairwise using 
post hoc t tests based on data from 
all groups and 1-way ANOVA.
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from all patients exhibited a strongly impaired ability to induce 
expression of IFNA2, IFNB, and IFNL1 upon stimulation with 
poly(dA:dT) (Figure 2, D–F). Importantly, this was not observed 
when we examined PBMCs from children with VZV infection 
not carrying mutations in the POL III genes (Figure 2G) or from 
donors who harbored other heterozygous mutations in POLR3A 
and POLR3C but had not experienced severe VZV infection (Sup-
plemental Figure 6). Moreover, cells from the patients responded 
normally to stimulation with transfected polyinosinic-polycytidylic 
acid [poly(I:C)] (Figure 2H), which stimulates the MAVS pathway 
at the level of RIG-like receptors downstream of POL III (35). To 
determine whether the identified phenotype in PBMCs was also 
observable in other cell types, we compared induction of IFNB 
expression in fibroblasts from a healthy donor and P3 after stim-
ulation with RNA or DNA or infection with VZV. In contrast to the 
observation in PBMCs, fibroblasts from P3 responded normally to 
poly(dA:dT) (Supplemental Figure 7A and data not shown). Inter-
estingly, immunoblotting revealed that the potent IFN-inducing 
DNA sensor cGAS was expressed at very low levels in PBMCs com-
pared with fibroblasts, monocyte-derived macrophages, and kera-
tinocytes (Supplemental Figure 7, B and C). Collectively, PBMCs 
from patients with mutations in genes encoding the POLR3A and 
POLR3C subunits of the POL III complex exhibited a reduced 
capacity to mount IFN expression in response to AT-rich DNA.
AT-rich regions from the VZV genome stimulate IFN expression in 
controls but not patient PBMCs. Since POL III initiates promoter- 
independent transcription from DNA regions with high AT content 
(26), we analyzed the VZV genome for AT content. The overall AT 
content in the VZV genome is 54%. Interestingly, the VZV genome 
included several islands with high AT content, between 70% and 
80% (Figure 3A). A comparison with other human pathogenic 
herpesviruses revealed that the abundance of AT-rich regions was 
very low in the genomes of HSV-1, HSV-2, and Epstein-Barr virus, 
whereas several AT-rich regions were found in the CMV genome, 
tions in POLR3C on the biophysical properties of the proteins, we 
expressed the WT and mutant proteins as His-tagged proteins in 
bacteria. This was not feasible with POLR3A, since this protein 
is poorly expressed from bacteria. All POLR3C forms could be 
expressed, and WT and R438G (P3) were precipitated with cobalt 
affinity resin (Supplemental Figure 4). By contrast, the L11F (P1) 
and R84Q (P4) mutants failed to bind the resin. This may suggest 
that the L11F and R84Q mutants have altered biophysical proper-
ties, the nature of which requires further investigation.
Induction of IFNs by AT-rich DNA in human PBMCs is POL 
III–dependent. In a first set of experiments, we aimed to evalu-
ate whether stimulation by AT-rich DNA in PBMCs induces IFN 
responses in a POL III–dependent manner. When PBMCs from 
healthy controls were incubated in the presence or absence of the 
POL III inhibitor ML60218, we observed that the inhibitor was able 
to block IFNA2 and IFNB expression induced by poly(dA:dT) but 
not by the TLR7/8 agonist R848 (Supplemental Figure 5). Stimu-
lation of sorted PBMC subpopulations revealed that CD14+CD16– 
monocytes induced the highest levels of IFNA2 in response to 
poly(dA:dT) (Figure 2A). The frequency of plasmacytoid den-
dritic cells (pDCs) in the thawed PBMC populations was low (0.2 
%), so we evaluated the impact of pDCs on poly(dA:dT)-induced 
IFN production by depleting this cell type prior to stimulation. 
The pDC-depleted PBMCs still induced robust, but significantly 
reduced, expression of IFNA2 (Figure 2B). These data demon-
strate that poly(dA:dT) induces IFN expression through the POL 
III pathway in PBMCs and stimulates specific cell populations, 
most notably classical monocytes.
Impaired AT-rich DNA–stimulated IFN production by PBMCs 
from POLR3A-, POLR3C-mutated patients. To start investigating 
the patient cells, we first examined the levels of 5S rRNA, which is 
transcribed in a POL III–dependent manner. Interestingly, PBMCs 
from the 4 patients were indistinguishable from control cells with 
respect to the levels of 5S rRNA (Figure 2C). By contrast, PBMCs 
Figure 3. AT content in herpesvirus genomes. (A) The content and distribution of AT-rich regions in the genomes of VZV were compared with those in the 
genomes of HSV-1, HSV-2, EBV, and CMV using the EMBOSS Isochore algorithm. Data are presented to show regions in the genome with AT content great-
er than 70% AT. The regions harboring the sequences termed “VZV-AT-high DNA” and “VZV-AT-low DNA” are indicated by blue and red stars, respectively. 
(B) Sequences and genome localization of “VZV-AT-high” and “VZV-AT-low” DNA. (C and D) PBMCs from P1–P4 and 3 controls were transfected with VZV-
AT-high or VZV-AT-low DNA (2 μg/ml). Total RNA was harvested 6 hours later, and levels of IFNA2 mRNA were determined by RT-qPCR. Data are presented 
as mean ± SD of 3 replicates from 3 independent experiments. UT, untreated. NS, P > 0.05; *0.01 < P < 0.05; **0.01 < P < 0.001; ***0.001 < P < 0.0001. 
Groups were compared pairwise using post hoc t tests based on data from all groups and 1-way ANOVA.
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although not to the same extent as in the VZV genome (Figure 
3A). From the VZV genome we selected two 72mers located in 
AT-high and AT-low clusters, respectively (Figure 3B). PBMCs 
from controls or patients were stimulated with VZV-AT-high and 
VZV-AT-low dsDNA, and induction of IFNA2 was examined. Sim-
ilar to what was observed after stimulation with poly(dA:dT), the 
cells from all 4 patients displayed impaired ability to induce IFNA2 
expression after stimulation with VZV-AT-high DNA (Figure 3C). 
In contrast to this, the response to VZV-AT-low DNA was less 
affected in patient cells (Figure 3D).
Impaired ability of patient cells to produce the immunostimu-
latory RNA PAMP. POL III transcribes AT-rich DNA to produce 
an RNA product carrying a tri-phosphate signature in the 5′ end 
(ppp-RNA) (26, 27). This RNA can serve as agonist for the RIG-I/
MAVS pathway (26, 27) (Figure 4A). To functionally charac-
terize the ability of POL III from patient cells to bind DNA, we 
used an assay where we immunoblotted for POL III subunits in 
poly(dA:dT) precipitates (Supplemental Figure 8, A and B). This 
assay showed that interaction between AT-rich DNA and POL 
III was impaired in lysates from P1, but not P2 and P3, compared 
with controls (Figure 4B). P4 was not examined due to the limited 
availability of material from this patient. To examine for produc-
tion of the immunostimulatory RNA PAMP, we adapted a proto-
col described previously (26, 27) (Figure 4C and Supplemental 
Figure 8C). Interestingly, RNA isolated from P1–P3 cells trans-
fected with poly(dA:dT) or VZV-AT-high DNA stimulated signifi-
cantly less IFNB mRNA expression as compared with RNA isolat-
ed from transfected cells from healthy donors (Figure 4, D and E). 
These data suggested that cells from patients with heterozygous 
mutations in the POLR3A and POLR3C genes may lead to func-
tional defects in the POL III DNA sensing system and impaired 
ability to convert AT-rich DNA into the immunostimulatory RNA 
PAMP, thus providing a molecular mechanism for the impaired 
IFN responses to AT-rich DNA of the patients’ PBMCs.
Reduced IFN induction in response to VZV infection in PBMCs 
from POLR3A-, POLR3C-mutated patients. To evaluate whether 
the POLR3A, POLR3C mutations also had an impact on the innate 
immune response to VZV infection, we treated PBMCs from con-
trols and the 4 patients with VZV-infected MeWo cells and evalu-
ated expression of type I and III IFNs, as well as ISGs. An initial 
characterization of the MeWo-PBMC coculture system revealed 
that viral replication occurred in both MeWo cells and PBMCs, 
whereas IFN expression was observed only in the PBMCs and only 
upon coculture with infected MeWo cells (Supplemental Figure 9, 
A and B). We observed that both cell-associated and cell-free virus 
induced IFN expression, and that full induction of IFN responses 
was dependent on viral gene expression, as indicated by its inhi-
bition by UV treatment (Supplemental Figure 9, C and D). VZV- 
infected MeWo cells did not produce detectable levels of IFNL1 
mRNA (Supplemental Figure 9B). For IFNA2 expression, PBMCs 
from P3 and P4, but not P1 and P2, showed reduced ability to 
induce this response during VZV infection (Figure 5A). For type 
III IFNs, P1, P3, and P4, but not P2, failed to induce IFNL1 expres-
sion in the VZV-infected cultures (Figure 5B). The impaired VZV- 
induced IFN expression in P1, P3, and P4 was translated into low-
er induction of the ISG CXCL10 (Figure 5C). The finding demon-
Figure 4. Impaired production of immunostimulatory 
RNA by patient cells after transfection with AT-rich 
DNA. (A) Schematic illustration of the pathways 
through which poly(dA:dT) and poly(I:C) induce IFN 
expression. (B) Poly(dA:dT) beads incubated with cyto-
plasmic extracts of PBMCs from healthy controls, P1, P2, 
and P3 were precipitated (precip) and immunoblotted 
with anti-POLR3A and anti-POLR3C. (C) Overview of 
the assay used to evaluate for POL III activity. (D and 
E) PBMCs from P1, P2, P3 and 4 healthy controls were 
transfected with poly(dA:dT) or VZV-AT-high DNA (2 
μg/ml). Total RNA was isolated 14 hours later and 
transfected into HEK293 cells. Total RNA was isolated 6 
hours later, and levels of IFNB mRNA were determined 
by RT-qPCR. The levels of IFNB mRNA were normalized 
to GAPDH, and data are presented as mean ± SD from 
3 replicates from 2 independent experiments. Lipo, 
Lipofectamine. *0.01 < P < 0.05; **0.01 < P < 0.001; 
***0.001 < P < 0.0001. Groups were compared pairwise 
using post hoc t tests based on data from all groups and 
1-way ANOVA.
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strates that although infection of MeWo cells with VZV stimulated 
only low IFN gene expression in control PBMCs, it lead to ISG 
expression, which, importantly, was abolished in cells from P1, P3, 
and P4. For P1, we examined for a wider range of ISGs, since we 
observed impaired induction of IFNL1 but not IFNA2. Important-
ly, P1 PBMCs failed to induce a large number of ISGs during VZV 
infection (Supplemental Figure 10). By comparison, PBMCs from 
children with VZV infection not carrying mutations in the POL III 
genes induced expression of IFNA2 and IFNL1 to the same extent 
as PBMCs from healthy children after VZV infection in vitro (Fig-
ure 5, D and E). Interestingly, when PBMCs from the family of P3 
were treated with VZV-infected MeWo cells, we observed that both 
children carrying the mutations failed to mount IFNL1 expression 
after VZV infection (Supplemental Figure 11A). The impaired IFN 
response to VZV infection was also observed in PBMCs from the 
father of P3, who did carry the same POL III mutations as P3, but 
the impairment was not as pronounced as observed in cells from 
the children with the mutations (Supplemental Figure 11A). PBMCs 
from the mother of P4, who is heterozygous for the same R84Q 
POLR3C mutation as P4 but does not carry P4’s other POLR3A 
mutation, displayed a normal response to VZV-infected MeWo 
cells, and hence the role of this R84Q POLR3C mutation in P4’s 
severe VZV infection remains unclear (major gene vs. modifier). 
We also noted that PBMCs from adults generally stimulated signifi-
cantly higher IFN expression after VZV infection than PBMCs from 
children (Supplemental Figure 11A). Immunoblotting revealed 
that the levels of cGAS, POLR3A, and POLR3C were expressed 
at comparable levels among the P3 family members (Supplemen-
tal Figure 11B), thus suggesting a more complex explanation for 
the age-dependent innate response to VZV infection than merely 
differential expression of DNA sensors. In summary, these data 
demonstrated that digenic mutations in POLR3A and POLR3C (P3 
and P4) were related to severe cellular phenotypes of IFN induction 
upon VZV infection in PBMCs, while milder cellular phenotypes 
were related to monogenic POLR3C mutation (P1), and monogenic 
POLR3A mutation was not related to impaired responses to VZV (P2).
Responses to other viruses in patients’ PBMCs. To examine wheth-
er the impaired IFN response to virus infection was specific to VZV, 
Figure 5. PBMCs from P1, P3, and P4 exhibit defective ability to produce IFNs during VZV infection and to control the virus. PBMCs from P1–P4 (A–C and 
F–H), 3 VZV patients not carrying POL III gene mutations (D and E), and age-matched healthy controls (A–H) were treated with VZV-infected MeWo cells. 
Total RNA was harvested 48 hours after initiation of coculture with VZV-MeWo cells. (F and G) PBMCs from P1–P4 and age-matched healthy controls were 
treated with IAV, measles virus, poliovirus, or reovirus (Reo) (all MOI 5). Total RNA was harvested 6 hours later. Levels of IFNA2, IFNL1, CXCL10, and Orf63 
mRNA were determined by RT-qPCR as indicated. For all PCR data, the levels of the mRNA of interest were normalized to GAPDH, and data are presented  
as mean ± SD of 3 replicates from 3 independent experiments. Average of 4 age-matched controls. NS, P > 0.05; *0.01 < P < 0.05; **0.01 < P < 0.001; 
***0.001 < P < 0.0001. Groups were compared pairwise using post hoc t tests based on data from all groups and 1-way ANOVA.
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Impaired control of VZV replication by PBMCs from POLR3A-, 
POLR3C-mutated patients. Finally, we evaluated whether patient 
cells exhibited impaired ability to control VZV replication. VZV- 
infected MeWo cells were cocultured with PBMCs from controls or 
each of the 4 patients, and we measured expression of viral Orf63, 
which is among the most abundant viral transcripts (36). Consistent 
with the impaired IFN responses to VZV by PBMCs from P1, P3, and 
P4, we observed that VZV infection in MeWo cells gave rise to sig-
nificantly higher viral gene expression when cocultured with PBMCs 
from P1, P3, or P4. By contrast, viral gene expression in cultures with 
P2 PBMCs was similar to that of the controls (Figure 5H), which is 
consistent with the normal IFN responses to VZV in P2 cells.
Reconstitution of WT POLR3C expression in P1 PBMCs rescues 
the control of VZV replication. To examine whether the impaired 
responses observed in patient cells were due to the mutations on 
we also infected POLR3A-, POLR3C-mutated patient PBMCs with 
HSV-1 and a panel of RNA viruses and measured accumulation 
of IFN transcript. While PBMCs from P1 exhibited reduced IFN 
expression after HSV-1 infection, the response in P2 and P3 was 
only marginally or not different from control cells (Supplemental 
Figure 12). Cells from P4 were not examined. With respect to RNA 
virus infections, all 4 patients’ cells responded with normal expres-
sion of type I and III IFNs to all viruses tested (Figure 5, F and G). 
Examination of the induction of IFNA2 and IFNL1 in cells from 
patients carrying mutations previously shown to confer susceptibil-
ity to HSE revealed that only IRF3 deficiency, but not TLR3 or TRIF 
deficiency, conferred reduced VZV-stimulated IFN expression 
(Supplemental Figure 13, A and B) (17, 18, 22). This IRF3 defect also 
ablated induction of IFNL1 by HSV-1 but did not affect the response 
to influenza A (IAV) infection (Supplemental Figure 13, C and D).
Figure 6. Rescue of WT POLR3 expression restores IFN response and control of VZV infection. (A) RNA was isolated from PBMCs from P1, which were 
either left untreated, or transduced with a lentivirus encoding WT or L11F POLR3C or carrying empty vector. Levels of POLR3C mRNA were determined by 
RT-qPCR. (B and C) The transduced P1 PBMCs were treated with poly(dA:dT) (2 μg/ml) or poly(I:C) (4 μg/ml). Total RNA was harvested 6 hours later, and 
levels of IFNL1 mRNA were determined by RT-qPCR. (D–F) The transduced P1 PBMCs were treated with VZV-infected MeWo cells. Total RNA was harvested 
48 hours later, and levels of IFNL1, IFNA2, and Orf63 mRNA were determined by RT-qPCR as indicated. (G) PBMCs from a healthy donor was transduced with 
a lentivirus encoding WT POLR3C or carrying empty vector. Levels of POLR3C mRNA were determined by RT-qPCR. (H and I) The transduced control PBMCs 
were treated with poly(dA:dT) (2 μg/ml) or with VZV-infected MeWo cells. Total RNA was harvested 6 and 48 hours later, respectively, and levels of IFNL1 
mRNA were determined by RT-qPCR as indicated. (J and K) RNA was isolated from PBMCs from P3, which were either left untreated, or transduced with a 
lentivirus encoding WT POLR3A, WT POLR3C, or carrying empty vector. Levels of POLR3A and POLR3C mRNA were determined by RT-qPCR. (L and M) The 
transduced P3 PBMCs were treated with poly(dA:dT) (2 μg/ml) or poly(I:C) (4 μg/ml). Total RNA was harvested 6 hours later, and levels of IFNL1 mRNA were 
determined by RT-qPCR. (N and O) The transduced P3 PBMCs were treated with VZV-infected MeWo cells. Total RNA was harvested 48 hours later, and 
levels of IFNL1 and Orf63 mRNA were determined by RT-qPCR as indicated. NS, P > 0.05; *0.01 < P < 0.05; **0.01 < P < 0.001; ***0.001 < P < 0.0001. Groups 
were compared pairwise using post hoc t tests based on data from all groups and 1-way ANOVA.
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genetic variations influencing RNA POL III function in noncoding 
regions of their genomes. PBMCs from the identified patients had 
impaired ability to induce expression of IFN in response to syn-
thetic AT-rich DNA only (P2, heterozygous for POLR3A M307V) 
or to both AT-rich DNA and VZV infection (P1, heterozygous for 
POLR3C L11F; P3, heterozygous for POLR3A Q707R and POLR3C 
R438G; P4 heterozygous for POLR3A R437Q and POLR3C 
R84Q). Reconstitution of expression of WT alleles enabled the P1 
and P3 cells to induce IFN expression in response to AT-rich DNA 
and VZV infection, and to control VZV infection. These immuno-
logical deficits probably account for the failure of P1, P3, and P4 
to control infection by VZV. In P3 and P4, the POLR3A, POLR3C 
digenic defect of POL III is the probable genetic cause of severe 
VZV infection. In P1, and perhaps in P2, POLR3C or POLR3A 
monogenic defect of POL III conferred the cellular and clinical 
phenotypes. The finding of milder in vitro defects for P2 is consis-
tent with his milder clinical phenotype, when compared with the 
other 3 patients. In these 4 families, there is incomplete clinical 
penetrance, with the possible exception of the P3 family, suggest-
ing that environmental factors, such as virus clades and infectious 
virus load, or host modifying factors, such as age of infection or 
modifying genes, are also involved in the pathogenesis.
The POL III complex consists of 17 subunits, 10 of which are 
specific for POL III (37). One question that arises based on the 
mutations identified in this study is why we identified mutations 
only in POLR3A and POLR3C. It is possible that future studies 
will lead to identification of mutations in other POL III subunits 
in patients with severe VZV infection and that the apparent bias 
observed in this study does not reflect the underlying biology of 
POL III in immunological DNA sensing. It may simply reflect the 
small size of our sample (21 patients). Second, it is possible that 
POL III can act in a modular fashion, with the requirement for 
different subunits being dependent on the DNA to be transcribed, 
e.g., promoter-dependent versus- independent transcription. 
Third, since all patients carry heterozygous mutations, and these 
mutations do not lead to total loss of function of POL III, it is pos-
sible that the different functions of POL III have differential toler-
ance for mutations in the different subunits. POLR3C, POLR3F, 
and POLR3G form a subcomplex that is required for transcription-
al initiation but not elongation by POL III, whereas the core POL 
III complex is required for elongation (37). We observed that the 
POLR3C mutants found in P1 and P4 had reduced solubility com-
pared with WT POLR3C. This may imply that a significant frac-
tion of the POL III complexes in P1 and P4 lack POLR3C, hence 
impairing the ability to transcribe RNA from AT-rich DNA. Lysates 
from all patients examined were strongly impaired in their abili-
ty to convert AT-rich DNA to immune-stimulatory RNA, whereas 
transcription of 5S rRNA was largely unaffected. Previous studies 
have identified mutations in POLR3A and POLR3B in patients 
with autosomal recessive 4H (hypomyelination, hypodontia, 
hypogonadotropic hypogonadism) leukodystrophy, which is a 
disease characterized by degeneration of the white matter in the 
brain (38–40). However, the functional impact of the POLR3 gene 
mutations in the 4H leukodystrophy patients on POL III activity 
remains to be established. Since defects in POL III are associated 
with both degenerative processes in the CNS and susceptibility to 
VZV in humans, there is a requirement for more knowledge on the 
POL III subunits, we wanted to reconstitute WT gene expression. 
Transduction of P1 PBMCs with lentivirus encoding WT or L11F 
POLR3C led to significantly higher levels of POLR3C mRNA com-
pared with those in cells transduced with a control lentivirus (Fig-
ure 6A). Importantly, cells from P1 transduced with WT, but not 
L11F, POLR3C gained the capacity to produce IFNL1 in response 
to poly(dA:dT), while the response to poly(I:C) was unaffected 
(Figure 6, B and C). Next, the transduced cells from P1 were 
infected with VZV, and levels of IFNL1, IFNA2, and Orf63 mRNAs 
were evaluated. Interestingly, in patient cells transduced with WT 
POLR3C but not in cells transduced with empty vector or L11F 
POLR3C, VZV infection induced IFNL1 expression (Figure 6D), 
and increased levels of IFNA2 (Figure 6E). The elevated induction 
of IFN in patient cells transduced with WT POLR3C was mirrored 
in reduced viral expression of Orf63 (Figure 6F). Transduction of 
WT POLR3C into cells from a healthy donor did elevate POLR3C 
mRNA levels, but did not affect IFNL1 expression after stimula-
tion with poly(dA:dT) or infection with VZV (Figure 6, G–I). Thus, 
reconstitution of WT POLR3C expression in P1 PBMCs restored 
the ability to induce IFN expression upon VZV infection and to 
control VZV replication.
Reconstitution of WT POLR3A and POLR3C expression in P3 
PBMCs rescues the control of VZV replication. P3 and P4 carry muta-
tions in both POLR3A and POLR3C, and we were interested in 
examining whether there was a requirement for correction of both 
mutations to mount innate immune responses. Therefore, cells 
from P3 were transduced with WT POLR3A and POLR3C (Figure 
6, J and K). Transduction of either WT subunit enabled the cells to 
induce IFNL1 in response to poly(dA:dT) and VZV without signifi-
cantly affecting the responsiveness to poly(I:C) (Figure 6, L–N). 
Transduction with both POLR3A and POLR3C led to a marginal, 
but not statistically significant, further elevation of the response 
to poly(dA:dT) and VZV. Finally, VZV replication was modestly 
impaired in cells incubated with patient PBMCs transduced with 
WT POLR3A, and was largely abrogated if incubated with patient 
PBMCs transduced with WT POLR3C or both POLR3A and 
POLR3C (Figure 6O). Collectively, the results indicate that the 
impaired ability of P1 and P3 PBMCs to produce IFNs in response 
to VZV was rescued by expression of the WT genes, which cor-
related with regained control of virus replication. A summary of 
the cellular phenotypes observed is shown in Supplemental Table 
6. Collectively, these reconstitution experiments established caus-
al relationships between monogenic POLR3C mutation (P1) or 
digenic POLR3A, POLR3C mutations (P3), and impaired antiviral 
IFN responses to VZV.
Discussion
One of the outstanding questions in human medicine and immu-
nology is why different individuals display differential suscep-
tibility to infections with a given microbe. In recent years, it has 
emerged that inborn errors in genes encoding proteins of innate or 
cell-intrinsic immunity can underlie specific infections in other-
wise healthy individuals (15, 16). In this work we describe 4 patients 
with severe VZV infections who carried missense mutations in 
POLR3A and/or POLR3C, which encode subunits of the innate 
DNA sensor POL III. Since this study was based on WES, it is pos-
sible that some of the remaining 17 patients with severe VZV have 
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Collectively, the results of this work demonstrate that func-
tional defects in two genes of the POL III pathway confer increased 
susceptibility to severe VZV infection, which is associated with 
impaired ability to detect foreign DNA with high AT content and 
mount antiviral IFN responses. This provides the first direct evi-
dence to our knowledge of a role for an innate DNA sensor in con-
trol of infections in humans.
Methods
Clinical information. Patients were retrospectively recruited using 
databases from hospitals and pediatric practices in Belgium, or recruit-
ed in the United States and in France, in accordance with local regula-
tions and with the approval of the IRB of the Antwerp University Hos-
pital, the Rockefeller University, and INSERM. Informed consent was 
obtained in the home country of each patient, in accordance with local 
regulations and with IRB approval. Patients were identified as having 
a severe VZV-related CNS or respiratory complication if (i) severe clin-
ical course led to hospitalization, (ii) the complication occurred within 
1 month after onset of chickenpox and no other reasons for the com-
plication were found, or (iii) CSF or tracheal suction material collected 
after the complication tested positive for VZV DNA using PCR. Time 
points for VZV infection and sampling were as follows: P1, episode 
occurred in 2010, sampling took place in 2014 and 2016; P2, episode 
occurred in 2011, sampling took place in 2014 and 2016; P3, episode 
occurred in 2010, sampling took place in 2010 and 2016; P4, episode 
occurred in 2007, sampling took place in 2007 and 2017.
Whole exome sequencing and bioinformatics. Genomic DNA was 
isolated from peripheral blood lymphocytes using standard proce-
dures. For P1 and P2, fragmentation of DNA was carried out on the 
Covaris M220. The TruSeq DNA Sample Preparation Kit LT (Illumi-
na) was used for adapter ligation and library amplification in order 
to prepare sample libraries for enrichment. Exome enrichment and 
capture were carried out using the SeqCap EZ Human Exome Library 
v3.0 kit (Nimblegen). Whole exome sequencing was performed on an 
Illumina HiSeq 1500 (Illumina) according to standard protocols for 
a paired end 2 × 100 bp high-throughput run. Reads were processed 
using an in-house pipeline as follows. Cutadapt (https://github.
com/marcelm/cutadapt) was used to trim adapter sequences, after 
which quality trimming, with a Phred score of 30 as threshold, was 
performed. Reads were mapped to the human reference genome 
(UCSC hg19) using the Burrows-Wheeler Aligner (BWA-MEM with 
default settings; http://bio-bwa.sourceforge.net/), and duplicates 
were removed using Picard (http://broadinstitute.github.io/picard/). 
According to the Genome Analysis Toolkit best practice guidelines 
local indel realignment and base quality recalibration were performed 
with recommended settings (GATK, https://software.broadinstitute.
org/gatk/). Variant Calling was performed using the Unified Geno-
typer both on the single-sample and multi-sample level, followed 
by merging of the resulting variant lists and variant quality recali-
bration. For P3 and P4, captured libraries were sequenced with the 
Illumina HiSeq2500 and Illumina HiSeq2000 sequencing platforms, 
respectively, and reads were mapped to the human reference genome 
assembly GRCh37 (UCSC hg19) using the Burrows-Wheeler Aligner. 
Variants were identified with the GATK, Sequence Alignment/Map 
(SAM) tools (http://samtools.sourceforge.net/), and Picard tools. 
Variant calls with a read coverage ≤2× and a Phred-scaled SNP quality 
≤20 were eliminated.
biochemistry of POL III in transcription of endogenous as well as 
exogenous types of DNA.
Our results demonstrated that stimulation of IFN expression by 
AT-rich DNA was reduced in PBMCs from patients, therefore con-
firming previous results on POL III as an innate sensor of AT-rich 
DNA (26, 27). The VZV genome was found to be rich in regions with 
high AT content, and we found that synthetic DNA derived from 
an AT-rich region of the genome stimulated significantly less IFN 
expression in patient compared with control cells. DNA derived 
from a region of the VZV genome with low AT content stimulated 
IFN expression in a manner less dependent on POL III, although 
the response in PBMCs from P1, P3, and P4 was still impaired. This 
suggests that high AT content renders DNA more potent as a PAMP 
for POL III, but also that DNA with low AT content can stimulate 
this pathway to some extent. In this context, it was interesting to 
note that IFN induction by infection with HSV-1, which has a very 
low genomic AT content, was also reduced in cells from P1. Since its 
discovery, cGAS has been thoroughly characterized and is emerg-
ing as a dominant DNA sensor (29, 41). Mice deficient in cGAS are 
highly susceptible to several viral infections, and most cell types fail 
to respond to DNA in the absence of cGAS (41, 42). However, it was 
shown that cGAS-deficient murine lung fibroblasts responded nor-
mally to poly(dA:dT), but did have an impaired response to other 
DNA species (41). Together with the results of the present study, 
these data suggest that cGAS is not the key sensor of AT-rich DNA 
in certain cell types. Interestingly, we observed that human PBMCs 
have low expression of cGAS compared with skin fibroblasts and 
monocyte-derived macrophages. This may explain the in vitro phe-
notype documented in PBMCs but not skin fibroblasts of patients, 
and may also provide clues as to why POL III mutations confer 
selective susceptibility to VZV infection.
A central part of the natural history of VZV infection is a 
viremic stage in T cells, from which the virus is delivered to the 
skin, sensory nerve cell bodies, and other locations (2, 43). By con-
trast, viremia is not believed to be important for the pathogene-
sis of HSE, and it is worth noting that we did not find significant 
enrichment of POLR3A or POLR3C mutations in our large data set 
of 222 patients with HSE. Therefore, we speculate that the elevat-
ed susceptibility to severe VZV infections in individuals with POL 
III mutations might be explained, at least partly, by the combined 
effect of the high AT content of the VZV genome and the low cGAS 
expression by blood cells. Impaired POL III–mediated VZV viral 
DNA sensing and the consequent low levels of IFN responses of 
POLR3A-, POLR3C-mutated PBMCs might be the key to VZV dis-
semination in the blood and severe complication in some organs 
such as the CNS and the lung. Therefore, the present work contrib-
utes insight into how individual mutations affecting central antivi-
ral pathways sometimes appear to present with a very narrow and 
selective infectious phenotype in patients. It will be interesting to 
explore further the role of POL III in innate immune responses to 
infection. Finally, the identification of POL III defects in patients 
with severe disseminated VZV infections, particularly those 
affecting the CNS and the lung, may have clinical implications, 
including decisions on prophylactic VZV vaccination or acyclovir 
treatment, genetic counseling of family members, and possibly 
management of disseminated VZV infection with type I IFN as 
previously suggested for HSE (44).
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by centrifugation at 250 g for 7 minutes. Propidium iodide was used to 
distinguish between live and dead cell populations. Acquisition and cell 
sorting were performed on a MoFlo Astrios (Beckman Coulter). A 4-way 
sort was performed; live PBMCs, dead PBMCs, live VZV-MeWo cells, 
and dead VZV-MeWo cells were sorted. Data analysis was performed 
using FlowJo v10. RNA was harvested from each population, and virus 
presence and IFN production were analyzed by real-time PCR.
Cell culture and stimulation. Frozen PBMCs were thawed in 50-ml 
tubes with 20 ml preheated media (RPMI-1640 w/l-glutamine [Bio-
west], 10% heat-inactivated FBS [Life Technologies], 1% penicillin/
streptomycin) before centrifugation at 350 g in 10 minutes. Normal 
adult human keratinocytes were obtained by trypsinization of skin sam-
ples from patients undergoing plastic surgery as previously described 
(45). Whole cell lysates were made from second-passage keratinocytes 
grown in serum-free keratinocyte medium supplemented with human 
recombinant epidermal growth factor, bovine pituitary extract, and 
gentamicin (all from Life Technologies/Invitrogen). For stimulation 
experiments, cells were distributed in 24-well tissue culture plates with 
0.5 × 106 cells per 300 μl media and incubated overnight at 37°C and 
5% CO2. PBMCs were transfected with 2 μg/ml poly(dA:dT) (CAYLA 
InvivoGen) or 4 μg/ml poly(I:C) using Lipofectamine (Life Technolo-
gies). The synthetic analogs were incubated with Lipofectamine for 20 
minutes before dropwise addition to the PBMCs. Furthermore, PBMCs 
were stimulated with different viruses: HSV-1 (F strain), IAV (PR8 strain, 
H1N1), measles virus (Edmonston strain), polio virus 1 (LSa strain), reo-
virus type 1 (Lang strain), VZV (ROka strain) (PBMC/MeWo-VZV ratio, 
1:1). One vial of VZV-infected MeWo cells was thawed, spun down at 
1,000 rpm for 10 minutes, and resuspended in 400 μl preheated media. 
From this solution, 30 μl was added to the wells to be stimulated with 
VZV. Cells were incubated for 6 hours, except for MeWo-PBMC cocul-
tures, which were incubated for 48 hours before cell lysis and RNA har-
vest. The stimulations were performed in duplicate, except IAV stimuli, 
which represent 5 biological replicates from two experiments. To isolate 
cell-free VZV, infected MeWo cells were freeze-thawed overnight. Fol-
lowing thawing, cells were scraped from the flask by mechanical collec-
tion using a cell scraper (Sigma-Aldrich). Cells were disrupted using a 
bath sonicator, 3 times for 1.5 minutes at 15-second intervals. The lysate 
was collected and used as cell-free virus. For UV inactivation, the soni-
cated solution was treated for 5 minutes on ice under a UV lamp.
Isolation of RNA to use for stimulation of cells. For isolation of total 
RNA from PBMCs (2.4 × 106 cells per 12 wells), cells were lysed in 
TRIzol (Invitrogen) 16 hours after stimulation with DNA (2 mg/ml). 
Nucleic acids were extracted with phenol and chloroform, and precip-
itated with isopropanol containing linear polyacrylamide (5 mg/ml). 
For some experiments, extracted RNA was treated as follows before 
transfection into recipient cells: DNase I (200 U/ml/mg RNA), RNase 
A (0.1 mg/ml/mg RNA) (Ambion), or alkaline phosphatase (AP; 100 
U/ml; Roche Applied Science) at 37°C for 1 hour. AP-treated RNA was 
incubated at 65°C for 15 minutes for heat inactivation before further 
treatment with PNK. Enzyme-treated RNAs were precipitated with 
isopropanol before transfection.
In vitro DNA binding assay. Cells (2 × 106) were resuspended in 
lysis buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 0.1% Nonidet-P40; 5 
mM EDTA; and 10% [vol/vol] glycerol), and the lysate was cleared by 
centrifugation for 15 minutes at 5,000 g. For precipitation with Neutr-
Avidin beads (Pierce), cell lysates were incubated for 2 hours with 
biotin-labeled poly(dA:dT). After incubation with NeutrAvidin beads, 
Variants were annotated and filtered using minor allele frequen-
cy <0.005 in the 1000 Genomes database; <0.01 in the ExAC, which 
contains WES data of 60,706 individuals; as well as the in-house WES 
database of the HGID laboratory, which contains WES data of 3,055 
individuals with diverse infectious diseases. We searched for rare 
nonsynonymous (including missense, stop loss or stop gain, start loss, 
in-frame or frame-shift insertions or deletions) and splicing cite muta-
tions, in a comprehensive list of genes known to be involved in IFN 
immunity (Supplemental Table 1), as well as in known PID genes.
Mutation validation by Sanger sequencing. For all patients, candi-
date mutations were verified by capillary sequencing using BigDye 
chemistry (Life Technologies). More precisely, primers to validate each 
of the variants were designed using Primer3 and ordered at Integrat-
ed DNA Technologies. The desired fragments were amplified by PCR 
using the GoTaq G2 PCR Master Mix (Promega). All reactions were 
carried out on a Thermal Cycler 2720 (Applied Biosystems). Primer 
sequences were POLR3A (P2): forward, 5′-AGCCTGTGACCTCCAAT-
CAG-3′, reverse, 5′-GACCCTCCGTTGTGAGTGAT-3′; POLR3A (P3): 
forward, 5′-TACAAACTATATCTAGCAGGC-3′, reverse 5′-ACCTC-
CAGGGTCTCCTCAG-3′; POLR3A (P4): forward, 5′-ATGGAGG-
CATCTTAGATTTG-3′, reverse, 5′-CAGTGCTACTCACCAGATG-3′; 
POLR3C (P1): forward, 5′-GCAGGCTTTCTTCATTTTTCCTT-3′, 
reverse, 5′-GCTTTTTCTTTCTTTGGACACAATAT-3′; POLR3C (P3): 
forward, 5′-GGCTAAGTAACTCCAGGTAG-3′, reverse, 5′-GTTC-
TATTTCAGCAGCTCAG-3′; POLR3C (P4): forward, 5′-CCATTTAG-
GTGAAGAAAGCC-3′, reverse, 5′-CTCCATGGTCTCTGTGAGC-3′. 
The samples were purified using calf intestinal alkaline phosphatase 
(Roche Life Science, 20 U/μl) and Exonuclease I (New England BioLabs, 
20,000 U/μl). Purified PCR products were bidirectionally sequenced 
using the BigDye Terminator v1.1 cycle sequencing kit (Applied Biosys-
tems) and separated on an ABI 3130XL Genetic Analyzer in accordance 
with the manufacturer’s instructions (Applied Biosystems).
Viral genome analysis. The content and distribution of AT-rich regions 
in herpesvirus genomes were analyzed using the EMBOSS Isochore 
algorithm (http://www.ebi.ac.uk/Tools/seqstats/emboss_isochore/) and 
publically available viral genome sequences. For the data presented, the 
parameters for the analysis were: window size, 50 bp; shift, 50 bp.
Cell sorting. Frozen PBMCs were thawed and stained, and the fol-
lowing populations (monoclonal antibodies used, all from BD Biosci-
ences) were sorted into cell culture plates: T cells (mouse anti–human 
CD3, clone UCHT1), B cells (mouse anti–human CD19, clone HIB19), 
classical and inflammatory monocytes (mouse anti–human CD14, 
clone M5E2; mouse anti–human CD16, clone 3G8). The purity of the 
cell populations was (donors 1, 2, 3): T cells: 100.0%, 98.2%, 99.2%; B 
cells: 99.2%, 99.5%, 99.8%; classical monocytes (CD14hiCD16–): 99.8%, 
100.0%, 99.8%; non-classical monocytes (CD14+CD16+): 95.4%, 92.2% 
(not analyzed for donor 3). pDCs were depleted using the Plasmacytoid 
Dendritic Cell Isolation Kit II, human kit (Miltenyi Biotech). For sorting 
of PBMCs and MeWo cocultures (ratio 1:1) into the respective popula-
tions, the cell culture supernatants were collected, with trypsinization 
of adherent cells, as well as mechanical collection using a cell scraper 
(Sigma-Aldrich). Cells and supernatants were centrifuged separately at 
250 g for 7 minutes, after which the two pellets were pooled in 10 ml 
buffer (PBS, 1% BSA, 2.5 mM EDTA, and 25 mM HEPES). Cells were 
incubated with 5 μl anti-CD45 antibody per 10 × 1010 cells/ml, with 1 × 
106 cells/ml kept as unstained control. All cells were incubated at 4°C 
for 30 minutes. After this, cells were washed in 10 ml buffer, followed 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
3 5 5 4 jci.org   Volume 127   Number 9   September 2017
1:500), POLR3C (Sigma-Aldrich, HPA027516, 1:250), cGAS (Cell 
Signaling Technology, 15102, 1:500), and β-actin (Abcam, ab49900, 
1:10,000). Peroxidase-conjugated secondary antibody (Jackson 
ImmunoResearch Laboratories Inc., HRP–anti-rabbit, 711-035-152, 
1:10,000) was used for development.
Generation of lentiviral constructs and reconstitution of POLR3A 
and POLR3C expression. For plasmid construction, POLR3C (Plas-
mID HsCD00321588) and POLR3A (GenScript OHu27038C) cDNAs 
were acquired commercially. The lentiviral vector constructs pCCL/
PGK-POLR3C and pCCL/PGK-POLR3A were produced by PCR 
amplification of POLR3C and POLR3A cDNA, respectively, and sub-
sequent insertion into XhoI-/BamHI-digested pCCL/PGK-eGFP (46) 
by NEBuilder HiFi DNA Assembly according to the manufacturer’s 
instructions (New England BioLabs). pCCL/PGK-POLR3C(L11F) 
was created by introducing a 36G>T point mutation into pCCL/PGK- 
POLR3C by NEBuilder HiFi DNA assembly. Production of lentiviral 
vectors has previously been described in detail (46). Briefly, packag-
ing plasmids pMDlg/p-RRE, pMD.2G, and pRSV-Rev were cotrans-
fected into HEK 293T cells with pCCL/PGK-POLR3C, pCCL/PGK- 
POLR3A, pCCL/PGK-POLR3C(L11F), or pCCL/PGK-eGFP using 
calcium phosphate transfection. Vector-containing supernatants 
were passed through 0.45-μM filters (Sarstedt) and ultracentrifuged 
through a 20% sucrose cushion for 2 hours at 100,000 g, 4°C. Pellets 
were resuspended in PBS and stored at –80°C. HIV-1 p24 concentra-
tions were measured by ELISA (XpressBio) according to the manufac-
turer’s instructions. For transductions, 500,000 PBMCs in 24-well 
plates were transduced with lentivirus at a concentration of 500 ng 
p24 per well. Two days later the cells were stimulated as shown.
In silico structural modeling of patient mutations. In silico structur-
al modeling of patient mutations was performed using the published 
crystal structure of yeast RNA POL III (30). The mutated residues 
found in P1 to P4 were located and displayed at the equivalent position 
in the yeast counterpart subunit using sequence alignment. The fig-
ures were prepared using PyMOL (http://www.pymol.org).
Bacterial coprecipitation experiments. Rosetta2 cells were trans-
formed with a pET-15b–derived plasmid harboring POLR3C with 
either a WT or mutated open reading frame. Each construct was ful-
ly sequenced in order to ensure the integrity of the DNA sequence. 
Cells were grown at 37°C, and 1/10 of the cell culture was saved as 
non-induced control (NI). Cells were induced with 1 mM ITPG for an 
overnight incubation at 15°C. Cells were harvested by centrifugation 
and resuspended in a buffer containing 1.5× PBS, 1 mM Mg acetate, 
0.1% NP-40, 20 mM imidazole, 10% glycerol (lysis buffer). The cell 
pellet was sonicated for 5 seconds at 7 W and centrifuged. About 10% 
of the supernatant was kept as the total lysate, and levels of POLR3C in 
the lysate were determined by Western blotting. The supernatant was 
incubated with cobalt-affinity resin for 30 minutes at 4°C. Beads were 
washed 3 times with 1 ml of the lysis buffer. About 5% of the crude 
extract and 15% of the bound fraction were analyzed on a 12.5% SDS-
PAGE and visualized by Coomassie blue staining.
Study approval. This study was approved by the ethics board of 
Antwerp University Hospital, and approved by the Institutional review 
board of the Rockefeller University. Written informed consent was 
obtained from the parents of all study participants younger than 18 
years old and all participants older than 12 years old.
Statistics. The gene expression data are presented as mean of 
4–5 observations ± SD. For statistical analysis, first the hypothesis of 
bound complexes were pelleted by centrifugation and analyzed by 
immunoblotting. For confirmation of binding specificity, assays were 
also performed in the presence or absence of increasing amounts (0.5, 
5, or 50 μg/ml) of unlabeled poly(dA:dT).
RNA isolation and reverse transcription PCR. RNA was harvest-
ed from patient and control PBMCs using a High Pure RNA Isolation 
Kit (Roche) and synthesized to cDNA using the QIAGEN QuantiTect 
Reverse Transcription Kit (catalog 205313) according to the manufac-
turer’s instructions. Real-time qPCR with TaqMan probes was used for 
measurement of mRNA levels of IFNA2, IFNB, IFNL1, CXCL10, IL6, 
5S rRNA, and GAPDH (PerfeCTa qPCR FastMix II, Quantabio, cata-
log 95119). The Taqman probes were IFNA2 (Hs00265051_s1), IFNB1 
(Hs01077958_s1), IFNL1 (Hs00601677_g1), CXCL10 (Hs01124251_
g1), IL6 (Hs00985639_m1), 5S rRNA (Hs03682751_gH), and GAPDH 
(Hs02758991_g1) (Thermo Fisher Scientific). The samples were ana-
lyzed in duplicate using the CFX96 Touch Real-Time PCR Detection Sys-
tem (Bio-Rad) at 95°C for 10 minutes, followed by 45 cycles of 95°C for 
30 seconds and 60°C for 1 minute. The levels of Orf63 were determined 
by RT-qPCR with a QuantiFast SYBR Green Kit (QIAGEN) using the 
following primer sequences: ORF63 forward: GCGCCGGCATGATA-
TACC and ORF63 reverse: GACACGAGCCAAACCATTGTA; GAPDH 
forward: TCTTTTGCGTCGCCAGCCGAG and GAPDH reverse: 
ACCAGGCGCCCAATACGACCA. The reactions were carried out on a 
CFX96 Touch Real-Time PCR Detection System (Bio-Rad) at 95°C for 
5 minutes, 45 cycles at 95°C for 10 seconds, and 62°C for 22 seconds.
Fluidigm. cDNA was prepared using a QuantiTect Reverse Tran-
scription kit (QIAGEN). For pre-amplication, cDNA was mixed with 
SuperScript III Taq RT Platinum mix (Invitrogen) and a 0.2× mix of all 
TaqMan gene expression assays (LifeTechnologies) used in the Flui-
digm assay (see below) and amplified using the following thermal cycle 
protocol: one incubation of 15 minutes at 50°C; one incubation of 2 min-
utes at 95°C; and 18 cycles of 15 seconds at 95°C and 4 minutes at 60°C. 
The amount of cDNA present in each samples was assessed by regu-
lar qPCR using a TaqMan gene expression assay for ACTB (see below) 
and the TaqMan RT-PCR mix (Applied Biosystems). Fluidigm-based 
qPCR was then performed on the BioMarker HD instrument using a 
Flex Six Integrated Fluidic Circuit (IFC) (Fluidigm) according to the 
manufacturer’s instructions. The Flex Six IFC was loaded using the 
HX IFC controller (Fluidigm). The Flex Six IFC was then placed in the 
BioMarker HD instrument. qPCR was performed using the “GE Flex-
Six Standard v1” thermal cycle protocol. The data were analyzed using 
Real-Time PCR Analysis software 4.1.3 (Fluidigm). As a Ct threshold 
method, the “auto (global)” method was used; for baseline correc-
tion, the “linear (derivative)” method was used. For all TaqMan gene 
expression assays, except ISG15, 0.65 was set as a quality threshold; 
for ISG15, 0.31 was set as a quality threshold. Data failing the quality 
call were removed from the analysis. Data were normalized to aver-
age of ACTB and GAPDH expression. Fold induction of genes due to 
treatment was calculated in reference to the untreated samples of each 
test subject. TaqMan gene expression assays used for Fluidigm anal-
ysis were: ACTB: Hs00357333_g1; GAPDH: Hs02758991_g1; IFNB: 
Hs01077958_s1; CXCL10: Hs01124252_g1; IFIT1: Hs03027069_s1; 
IFIT2: Hs00533665_m1; ISG15: Hs00192713_m1; ISG20: Hs00158122_
m1; MX1: Hs00895608_m1; OAS1: Hs00973637_m1.
Western blotting. Total cell lysates were subjected to SDS-PAGE 
and immunoblotting. The blots were blocked with 5% milk and probed 
with the following primary antibodies: POLR3A (Abcam, ab96328, 
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a common mean in the groups was tested using an F-test based on a 
1-way ANOVA. When there was evidence against the hypothesis of a 
common mean, groups were compared pairwise using post hoc t tests 
(i.e., based on data from all groups and 1-way ANOVA). A P value less 
than 0.05 was considered significant.
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